5T3X
 
 | |
5UEM
 | | Crystal structure of 354NC37 Fab in complex with HIV-1 clade AE strain 93TH057 gp120 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 354NC37 Fab Heavy Chain, ... | | Authors: | Sievers, S.A, Gristick, H.B, Bjorkman, P.J. | | Deposit date: | 2017-01-02 | | Release date: | 2018-01-10 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.
Sci Transl Med, 9, 2017
|
|
5UD9
 | | Crystal structure of 354BG18 Fab | | Descriptor: | Fab heavy chain, Light chain | | Authors: | Scharf, L, Bjorkman, P.J. | | Deposit date: | 2016-12-23 | | Release date: | 2017-02-01 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (1.3 Å) | | Cite: | Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.
Sci Transl Med, 9, 2017
|
|
5UEL
 | | Crystal structure of 354NC102 Fab | | Descriptor: | 354NC102 Fab Heavy Chain, 354NC102 Fab Light Chain, SULFATE ION | | Authors: | Sievers, S.A, Gristick, H.B, Bjorkman, P.J. | | Deposit date: | 2017-01-02 | | Release date: | 2017-02-01 | | Last modified: | 2022-04-13 | | Method: | X-RAY DIFFRACTION (1.6 Å) | | Cite: | Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.
Sci Transl Med, 9, 2017
|
|
5VIC
 | | Crystal structure of anti-Zika antibody Z004 bound to DENV-1 Envelope protein DIII | | Descriptor: | Dengue 1 Envelope DIII domain, Fab heavy chain, Fab light chain | | Authors: | Keeffe, J.R, West Jr, A.P, Gristick, H.B, Bjorkman, P.J. | | Deposit date: | 2017-04-14 | | Release date: | 2017-05-03 | | Last modified: | 2017-05-17 | | Method: | X-RAY DIFFRACTION (3 Å) | | Cite: | Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.
Cell, 169, 2017
|
|
5VIY
 | |
5VIG
 | | Crystal structure of anti-Zika antibody Z006 bound to Zika virus envelope protein DIII | | Descriptor: | CITRATE ANION, Fab heavy chain, Fab light chain, ... | | Authors: | Keeffe, J.R, West Jr, A.P, Gristick, H.B, Bjorkman, P.J. | | Deposit date: | 2017-04-16 | | Release date: | 2017-05-03 | | Last modified: | 2017-05-17 | | Method: | X-RAY DIFFRACTION (3 Å) | | Cite: | Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.
Cell, 169, 2017
|
|
1DQG
 | | CRYSTAL STRUCTURE OF THE CYSTEINE RICH DOMAIN OF MANNOSE RECEPTOR | | Descriptor: | MANNOSE RECEPTOR, SULFATE ION | | Authors: | Liu, Y, Chirino, A.J, Misulovin, Z, Leteux, C, Feizi, T, Nussenzweig, M.C, Bjorkman, P.J. | | Deposit date: | 2000-01-04 | | Release date: | 2000-05-10 | | Last modified: | 2011-07-13 | | Method: | X-RAY DIFFRACTION (1.7 Å) | | Cite: | Crystal structure of the cysteine-rich domain of mannose receptor complexed with a sulfated carbohydrate ligand.
J.Exp.Med., 191, 2000
|
|
1DQO
 | | Crystal structure of the cysteine rich domain of mannose receptor complexed with Acetylgalactosamine-4-sulfate | | Descriptor: | 2-acetamido-2-deoxy-4-O-sulfo-beta-D-galactopyranose, MANNOSE RECEPTOR | | Authors: | Liu, Y, Chirino, A.J, Misulovin, Z, Leteux, C, Feizi, T, Nussenzweig, M.C, Bjorkman, P.J. | | Deposit date: | 2000-01-04 | | Release date: | 2000-05-10 | | Last modified: | 2023-08-09 | | Method: | X-RAY DIFFRACTION (2.2 Å) | | Cite: | Crystal structure of the cysteine-rich domain of mannose receptor complexed with a sulfated carbohydrate ligand.
J.Exp.Med., 191, 2000
|
|
1EXU
 | | CRYSTAL STRUCTURE OF THE HUMAN MHC-RELATED FC RECEPTOR | | Descriptor: | BETA-2-MICROGLOBULIN, BETA-MERCAPTOETHANOL, IGG RECEPTOR FCRN LARGE SUBUNIT P51 | | Authors: | West Jr, A.P, Bjorkman, P.J. | | Deposit date: | 2000-05-04 | | Release date: | 2000-08-10 | | Last modified: | 2023-08-09 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,).
Biochemistry, 39, 2000
|
|
1FJR
 | | CRYSTAL STRUCTURE OF THE ECTODOMAIN OF METHUSELAH | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, LEAD (II) ION, ... | | Authors: | West Jr, A.P, Llamas, L.L, Snow, P.M, Benzer, S, Bjorkman, P.J. | | Deposit date: | 2000-08-08 | | Release date: | 2001-04-04 | | Last modified: | 2020-07-29 | | Method: | X-RAY DIFFRACTION (2.3 Å) | | Cite: | Crystal structure of the ectodomain of Methuselah, a Drosophila G protein-coupled receptor associated with extended lifespan.
Proc.Natl.Acad.Sci.USA, 98, 2001
|
|
1FWV
 | |
1FWU
 | |
1G0X
 | |
1I1C
 | | NON-FCRN BINDING FC FRAGMENT OF RAT IGG2A | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[beta-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, IG GAMMA-2A CHAIN C REGION | | Authors: | Martin, W.L, West Jr, A.P, Gan, L, Bjorkman, P.J. | | Deposit date: | 2001-01-31 | | Release date: | 2001-02-14 | | Last modified: | 2023-08-09 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding.
Mol.Cell, 7, 2001
|
|
1I1A
 | | CRYSTAL STRUCTURE OF THE NEONATAL FC RECEPTOR COMPLEXED WITH A HETERODIMERIC FC | | Descriptor: | 2-acetamido-2-deoxy-alpha-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, ... | | Authors: | Martin, W.L, West Jr, A.P, Gan, L, Bjorkman, P.J. | | Deposit date: | 2001-01-31 | | Release date: | 2001-02-14 | | Last modified: | 2023-12-13 | | Method: | X-RAY DIFFRACTION (2.8 Å) | | Cite: | Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding.
Mol.Cell, 7, 2001
|
|
7K8Q
 | | Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment, C121 | | Descriptor: | C121 Fab Heavy Chain, C121 Fab Light Chain, GLYCEROL | | Authors: | Abernathy, M.E, Barnes, C.O, Bjorkman, P.J. | | Deposit date: | 2020-09-27 | | Release date: | 2020-10-21 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (2 Å) | | Cite: | SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
Nature, 588, 2020
|
|
7K8Y
 | | Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C121 (State 2) | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, C121 Fab Heavy chain, C121 Fab Light chain, ... | | Authors: | Abernathy, M.E, Barnes, C.O, Bjorkman, P.J. | | Deposit date: | 2020-09-27 | | Release date: | 2020-10-21 | | Last modified: | 2021-01-13 | | Method: | ELECTRON MICROSCOPY (4.4 Å) | | Cite: | SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
Nature, 588, 2020
|
|
7K8N
 | | Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment, C102 | | Descriptor: | C102 Fab Heavy Chain, C102 Fab Light Chain, DI(HYDROXYETHYL)ETHER, ... | | Authors: | Jette, C.A, Barnes, C.O, Bjorkman, P.J. | | Deposit date: | 2020-09-27 | | Release date: | 2020-10-21 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (1.65 Å) | | Cite: | SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
Nature, 588, 2020
|
|
7K8X
 | | Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C121 (State 1) | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, C121 Fab Heavy chain, C121 Fab Light chain, ... | | Authors: | Abernathy, M.E, Barnes, C.O, Bjorkman, P.J. | | Deposit date: | 2020-09-27 | | Release date: | 2020-10-21 | | Last modified: | 2021-01-13 | | Method: | ELECTRON MICROSCOPY (3.9 Å) | | Cite: | SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
Nature, 588, 2020
|
|
7K8P
 | |
7K8S
 | | Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C002 (state 1) | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, C002 Fab Heavy Chain, ... | | Authors: | Barnes, C.O, Malyutin, A.G, Bjorkman, P.J. | | Deposit date: | 2020-09-27 | | Release date: | 2020-10-21 | | Last modified: | 2021-01-13 | | Method: | ELECTRON MICROSCOPY (3.4 Å) | | Cite: | SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
Nature, 588, 2020
|
|
7K8R
 | | Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment, C135 | | Descriptor: | C135 Fab Heavy Chain, C135 Fab Light Chain, GLYCEROL | | Authors: | Jette, C.A, Barnes, C.O, Bjorkman, P.J. | | Deposit date: | 2020-09-27 | | Release date: | 2020-10-21 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (2 Å) | | Cite: | SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
Nature, 588, 2020
|
|
7K8Z
 | |
7K8M
 | | Structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody Fab fragment, C102 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, C102 Fab Heavy Chain, C102 Fab Light Chain, ... | | Authors: | Jette, C.A, Barnes, C.O, Bjorkman, P.J. | | Deposit date: | 2020-09-27 | | Release date: | 2020-10-21 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (3.2 Å) | | Cite: | SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
Nature, 588, 2020
|
|
